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Introduction: The polymeric immunoglobulin receptor (PIGR) has been proposed to be a candidate prognostic
biomarker in a few cancer forms, and one previous study reported that reduced PIGR expression signifies more
aggressive tumours of the distal esophagus and gastroesophageal junction (GEJ). In the present study, we
examined the expression, clinicopathological correlates and prognostic significance of PIGR expression in an
extended cohort of adenocarcinoma of the upper gastrointestinal tract.
Materials and methods: Immunohistochemical PIGR expression was examined in a consecutive cohort of patients
with surgically resected, radio-chemonaive adenocarcinoma of the esophagus, GE-junction and stomach (n = 173),
including paired samples of benign-appearing squamous epithelium (n = 51), gastric mucosa (n = 114), Barrett’s
esophagus (BE) or intestinal metaplasia (IM) (n = 57) and lymph node metastases (n = 75). Non-parametric tests were
applied to explore associations between PIGR expression in primary tumours and clinicopathological characteristics.
Classification and regression tree analysis was applied for selection of prognostic cut-off. The impact of PIGR expression
on overall survival (OS) and recurrence-free survival (RFS) was assessed by Kaplan-Meier analysis and hazard ratios (HR)
calculated by adjusted and unadjusted Cox proportional hazards modelling.
Results: PIGR expression was significantly higher in intestinal metaplasia (BE or gastric IM) compared to normal tissues
and cancer (p < 0.001). Reduced PIGR expression in primary tumours was significantly associated with more advanced
tumour stage (p = 0.002) and inversely associated with involved margins (p = 0.034). PIGR expression did not differ
between primary tumours and lymph node metastases. There was no significant difference in PIGR expression between
tumours with and without a background of intestinal metaplasia. High PIGR expression was an independent predictor
of a prolonged OS (HR = 0.60, 95% CI 0.36-0.99) and RFS (HR = 0.49, 95% CI 0.27-0.90) in patients with radically resected
(R0) primary tumours and of an improved RFS (HR = 0.32, 95% CI 0.15-0.69) in curatively treated patients with R0
resection/distant metastasis-free disease.
Conclusion: High PIGR expression independently predicts a decreased risk of recurrence and an improved survival in
patients with adenocarcinoma of the upper gastrointestinal tract. These findings are of potential clinical relevance and
merit further validation.
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The incidence and death rates from gastric cancer are
steadily decreasing in the westernized world, but it still
remains the second most common cause of cancer death
worldwide [1]. In contrast, there has been a 2.5-fold
increase of gastro-esophageal junction (GEJ) adenocar-
cinoma (AC) over the last four decades [2]. The increase
is attributable at least in part to the known risk factors for
development of GEJAC; smoking, obesity and GE reflux
disease. Esophageal carcinoma rates are also increasing
and it is now the eighth most common cancer worldwide
[3-5]. As for GEJAC, there is a sharp increase for esopha-
geal adenocarcinoma and the incidence now surpasses
squamous cell carcinoma in Europe and America [4,6].
The late onset of symptoms, e.g. dysphagia, and the
early spread to regional lymph nodes explain the still
dismal 5-year survival rates of 15-25% [3,7] and there is
an apparent need for improved prognostic and treat-
ment predictive markers in upper gastrointestinal tract
carcinomas as a group.
The polymeric immunoglobulin receptor (PIGR) is a
member of the immunoglobulin superfamily and trans-
ports immunoglobulin A (IgA) onto mucosal surfaces.
PIGR binds polymeric IgA at the basolateral surface of
epithelial cells and the complex is then transcytosed to
the apical cell surface, where the extracellular part of
PIGR is cleaved off as a secretory component (SC) bound
to polymeric IgA. The extracellular component of PIGR
can also be cleaved off to produce SC without being
bound to IgA molecules and then acts as a scavenger on
the mucosal lining [8].
PIGR has been described as a putative cancer bio-
marker in a few studies on different cancer forms, the
majority of which indicate an association between low
PIGR expression and more aggressive disease. In a small
case series (n = 42) Gologan et al. found PIGR-negative
adenocarcinomas in the distal esophagus and GEJ to
be associated with lymph node metastasis and a trend
towards reduced survival [9]. Low PIGR expression has
also been shown to correlate with progression from
colon adenoma to carcinoma [10] and with poor prog-
nosis in colon cancer [11]. Furthermore, loss of PIGR
expression has been linked to tumour progression in
non-small cell lung cancer [12] while overexpression
of PIGR has been associated with the less aggressive
type 1 endometrial cancer [13] as well as correlating with
a better prognosis in bladder cancer [14] and epithelial
ovarian cancer [15]. However, contradicting data was
reported in a study on hepatitis B-derived hepatocellu-
lar carcinoma, where high PIGR expression was found
to be associated with greater metastatic potential and
poor prognosis [16].
The aim of this study was to examine the expression
and prognostic impact of PIGR in a consecutive cohortof adenocarcinoma of the esophagus, GEJ and stomach
(n = 173).
Methods
Study design and participants
The study comprised a consecutive cohort of 303 patients
with esophageal and gastric adenocarcinomas who had
been surgically treated in the university hospitals of Lund
and Malmö from Jan 1st 2006 – Dec 31st 2010. A total
number of 128 patients were excluded; all patients who
had received neoadjuvant treatment (n = 31), cases with
metastases from other cancers (n = 12), mucosal resections
(n = 6), consultancies from other departments (n = 22),
cases with missing archival specimens (n = 2) and double/
incorrectly coded cases (n = 55). The selected tumours
were histopathologically re-examined, including confirm-
ation of diagnosis and number of lymph nodes with
metastasis (re-classified following the standardized TNM
7 classification). Clinical data, and information on recur-
rence, vital status and cause of death was obtained from
the medical charts.
Patient and tumour characteristics are described in
Table 1.
Ethical permission was received from the regional
ethical board of Lund University (ref nr 445/07).
Tissue microarray construction
Tissue microarrays (TMAs) were constructed using a semi-
automated arraying device (TMArrayer, Pathology Devices,
Westminister, MD, USA). Duplicate tissue cores (1 mm)
were obtained from primary tumours. In addition, lymph
node metastases were sampled in 81 cases, intestinal
metaplasia (IM), either Barrett’s esophagus (BE) or gastric
IM, in 73 cases, normal squamous epithelium in 96 cases
and normal gastric mucosa in 131 cases. Duplicate cores
were obtained from different blocks of the primary
tumour and different lymph node metastases in cases
with more than one metastasis. Normal squamous epithe-
lium and gastric mucosa was represented in single cores,
and intestinal metaplasia in 1–3 cores.
Immunohistochemistry and staining evaluation
For immunohistochemical analysis of PIGR expression,
4 μm TMA-sections were automatically pre-treated using
the PT Link system and then stained in an Autostainer Plus
(DAKO; Glostrup, Copenhagen, Denmark) with a poly-
clonal, monospecific antibody; HPA012012, Atlas Anti-
bodies AB, diluted 1:200. The specificity of the antibody
was confirmed by immunofluorescence, Western blotting
and protein arrays (www.proteinatlas.org).
PIGR was exclusively expressed in the cytoplasm and cell
membrane. The staining was annotated by two observers
(RF, AG) whereby consensus for each core was reached in
estimated fraction 0.0-1.0 (1 = 100%) of stained cells, while
Table 1 Patient and tumour characteristics in the entire cohort and according to tumour location
Factor
Entire cohort (n = 175)
n (%)
Esophagus (n = 60)
n (%)
GE-junction (n = 45)
n (%)




Mean 70.2 76.9 69.9 72.0 0.080
Median 69.8 66.02 68.7 72.6
(Range) 42.6-94.4 48.2-88.5 48.7-88.5 42.6-94.4
Sex
Women 41 (23.4) 6 (10.0) 12 (26.7) 20 (30.3) 0.007
Men 134 (76.6) 54 (90.0) 33 (73.3) 46 (69.7)
T stage
1 19 (11.0) 9 (15.3) 3 (6.8) 6 (9.2) 0.265
2 32 (18.6) 10 (16.9) 4 (9.1) 17 (26.2)
3 94 (54.7) 34 (57.6) 33 (75.0) 26 (40.0)
4 27 (15.7) 6 (10.2) 4 (9.1) 16 (24.6)
Missing 3 1 1 1
Resection margins
R0 122 (69.7) 38 (63.3) 30 (66.7) 51 (77.3) 0.016
R1 34 (19.4) 10 (16.7) 11 (24.4) 12 (18.2)
R2 19 (10.9) 12 (20.0) 4 (8.9) 3 (4.5)
Examined nodes
Mean 29.0 36.6 29.7 25.8 <0.001
Median 30.2 33.5 28.00 23.0
Range 1-112 10-72 8-48 1-112
Missing 14 2 1 11
N stage
0 59 (33.7) 15 (25.0) 12 (26.7) 28 (42.4) 0.032
1 30 (17.1) 11 (18.3) 7 (15.6) 12 (18.2)
2 41 (23.4) 15 (25.0) 14 (31.1) 12 (18.2)
3 45 (25.7) 19 (31.7) 12 (26.7) 14 (21.2)
M stage
0 137 (88.4) 51 (86.4) 40 (88.9) 45 (91.8) 0.377
1 18 (11.6) 8 (13.6) 5 (11.1) 4 (8.2)
Missing 20 1 19
Differentiation grade
High 6 (4.0) 3 (5.9) 1 (2.5) 1 (1.8) 0.002
Intermediate 40 (26.8) 21 (41.2) 9 (22.5) 9 (16.4)
Low 103 (69.1) 27 (52.9) 30 (75.0) 45 (81.8)
Missing 26 9 5 11
Adjuvant radio/chemotherapy
No 150 (85.7)) 54 (93.1) 39 (90.7) 55 (85.9) 0.196
RT 1 (0.6) 1 0 0
CT with oxaliplatin 2 (1.1) 0 0 2 (3.1)
CT without oxaliplatin 3 (1.7) 0 2 (4.7) 1 (1.6)
RT + CT without oxaliplatin 6 (3.4) 2 (3.4) 2 (4.7) 2 (3.1)
RT + CT, NOS 2 0 0 2 (3.1)
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Table 1 Patient and tumour characteristics in the entire cohort and according to tumour location (Continued)
Yes, NOS 3 (1.7) 1 (1.7) 0 2 (3.1)
Unknown 8 2 2 2
Location
Esophagus 60 (35.1) - - -
GE-junction 45 (26.3) - - -
Stomach 66 (38.6) - - -
Unknown 4
Follow-up
Mean 2.92 2.97 2.87 2.92 0.848
Median 2.27 2.65 2.17 2.15
Range 0.01-7.70 0.26-7.70 0.01-7.64 0.03-7.60
Vital status
Alive 64 (36.6) 27 (45.0) 14 (31.1) 22 (33.3) 0.184
Dead 111 (63.4) 33 (55.0) 31 (68.9) 44 (66.7)
Recurrence
No 64 (46.4) 24 (46.2) 14 (38.9) 25 (50.0) 0.705
Yes 74 (53.6) 28 (53.8) 22 (61.1) 25 (50.0)
Unknown 37 8 9 16
*Chi-square test and Fisher’s Exact test was applied for analysis of differences in the distribution of clincipathological characteristics according to tumour location,
not including the entire cohort.
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2 =moderate and 3 = strong intensity. A multiplier of inten-
sity (0–3) and fraction (0.0-1.0) for each core was calculated
and a mean value of all annotated cores was used in the
analyses.
Statistical analysis
Non-parametric Mann–Whitney U and Kruskal-Wallis
tests were applied for analyses of differences in the
distribution of PIGR expression according to clinico-
pathological characteristics, in the entire cohort and
according to tumour location. The Chi-square test and
Fisher’s Exact test were used to analyse differences in
the distribution of clinicopathological characteristics
according to tumour location. Classification and regres-
sion tree (CRT) analysis [17] was used to assess optimal
prognostic cut off for PIGR expression in overall survival
(OS) and recurrence free survival (RFS). Kaplan Meier
analysis and the log rank test were applied to estimate
differences in OS and RFS in strata according to high
and low PIGR expression. RFS was defined from the date
of surgery to the date of locoregional or distant recurrence.
Cox regression proportional hazard’s modelling was used
to estimate the impact of PIGR expression on OS and RFS
in both unadjusted analysis and in a multivariable model
adjusted for, age, sex, T-stage, N-stage, M-stage, differenti-
ation, resection margins and tumour location. Some
subjects had no information on one or several markers
and missing values were coded as a separate categoryfor categorical variables. Missing values for categorical
variables co-varied and the adjusted model did not con-
verge due to many constant values. In order to avoid
this, only patients with information on PIGR expression
were included in the adjusted analysis. A backward con-
ditional method was used for variable selection in the
adjusted model. All test were two sided. P-values <0.05
were considered significant. All statistical analyses were
performed using IBM SPSS Statistics version 22.0 (SPSS
Inc., Chicago, IL, USA).
Results
PIGR expression in normal tissues, intestinal metaplasia,
primary tumours and lymph node metastases
Sample IHC images are shown in Figure 1 and the distri-
bution of PIGR staining (total score of fraction × intensity)
was evaluated in normal tissues, IM, primary tumours and
lymph node metastases is shown in Figure 2. All samples
of squamous epithelium (=51) were negative for PIGR
expression, in contrast to IM (n = 57) where PIGR expres-
sion was significantly higher than in all other tissues. In
mucosa with IM, PIGR was strongly expressed in the
majority of the cells, not only goblet cells, irrespective
of the anatomical origin, i.e. BE or gastric IM, and of
the presence or absence of dysplasia. In normal gastric
mucosa (n = 114), PIGR was expressed both in the glan-
dular cells and in the columnar epithelium in various
fractions but with all over weaker intensity than in IM.
PIGR expression could be evaluated in 173/175 (98,9%)
Figure 1 Sample immunohistochemical images of PIGR staining. Images (10× magnification) of PIGR expression in different tissue entities from
three cases. The mean score corresponds to the value of the sum of the fraction × intensity of all annotated cores. From left to right: (1) normal gastric
mucosa (mean/total score 0.70), intestinal metaplasia (mean/total score 3), primary tumour (mean/total score 0.2) and metastasis (mean/total score 0)
in a T3N3M1 gastric cancer, (2) squamous epithelium (mean/total score 0), Barrett’s esophagus (mean/total score 3), two cores from primary tumour
(score 2 and 0.2, respectively, mean/total score 1.1) in a T2N2M0 esophageal cancer, (3) squamous epithelium (mean/total score 0), normal gastric
mucosa (mean/total score 2.0), and two cores from primary tumour (both score 3, mean/total score 3) from a T3N3M0 GE-junction cancer.
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sampled lymph node metastases. A total number of 47/
173 (27.2%) of primary tumours and 32/75 (42.7%) of
lymph node metastases were negative for PIGR expres-
sion. There was no heterogeneity between duplicate tissue
cores in negative and strongly positive cases. PIGR expres-
sion did not differ significantly between primary tumours
and lymph node metastases, although a tendency towards
lower expression was seen in lymph node metastases
(p = 0.058, Figure 2A). As shown in Figure 2B there was
no significant difference in PIGR expression between
primary tumours or lymph node metastases in cases with
or without associated IM.
Associations of PIGR expression with clinicopathological
characteristics
As demonstrated in Table 2 there was a significant as-
sociation between reduced PIGR expression and a more
advanced T-stage (p = 0.002) and involved resection mar-
gins (p = 0.034) in the entire cohort. There were no
significant associations between PIGR expression and
any other clinicopathological parameters in the entire
cohort. The significant association of PIGR with T-stage
was retained in esophageal cancer (p = 0.006), while in
gastric cancer, PIGR expression was significantly associ-
ated with a more advanced N-stage (p = 0.043).
Prognostic significance of PIGR expression
According to the results of the CRT analysis a cut off at
0.922 was adopted for OS and 0.356 for RFS (Additional
file 1). As demonstrated in Figure 3A, there was a non-
significant trend towards an improved OS for cases with
high tumour-specific PIGR expression (p = 0.054). In caseswith radically resected (R0) primary tumours there was
a significant association between high PIGR expression
and a prolonged OS (p = 0.030, Figure 3B). There was a
significant association between high PIGR expression and
an improved RFS in cases with R0 resection (p = 0.015,
Figure 3C) and in curatively treated patients with R0
resection and no distant metastases (M0, p = 000.2,
Figure 3D). As demonstrated in Table 3, the significant
association of PIGR expression and a prolonged OS
was confirmed in unadjusted Cox regression analysis
(HR 0.58, 95% CI 0.36-0.96, p = 0.032), and remained
significant in adjusted analysis (HR 0.60, 95% CI 0.36-
0.99, p = 0.044). As further shown in Table 4, PIGR
expression was significantly associated with prolonged
RFS in unadjusted analysis for cases with R0 resection
(HR 0.49, 95% CI 0.27-0.88, p = 0.017) and curatively
treated patients with R0 resection/M0 disease (HR
0.37, 95% CI 0.19-0.72, p = 0.004). These associations
remained significant in adjusted analysis (HR 0.49, 95%
CI 0.27-0.90, p = 0.021 and HR 0.32, 95% CI 0.15-0.69,
p = 0.004, respectively).
Subgroup analysis according to anatomical tumour loca-
tion revealed that the prognostic impact of PIGR expression
was most evident in esophageal cancer for OS and
esophageal/GE junction cancer for RFS (Figure 4). Of note,
tumour location was not prognostic, neither for OS nor
RFS (data not shown). PIGR expression did not remain an
independent prognostic factor in subgroup analysis accord-
ing to tumour location (data not shown).
Discussion
The results from this study demonstrate that high PIGR
expression is an independent favourable prognostic factor
Figure 2 PIGR expression in normal tissues, intestinal metaplasia, primary tumours and metastases. (A) Box plots visualizing the distribution
of PIGR expression (total score) in normal squamous epithelium, intestinal metaplasia (Barrett’s esophagus or gastric intestinal metaplasia), primary tumours
and metastases in the entire cohort, and (B) primary tumours and metastases in cases with and without reported Barrett’s esophagus/
intestinal metaplasia, respectively.
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These findings are in line with the study by Gologan et al.
encompassing a smaller cohort of 42 adenocarcinomas
of the esophagus, GEJ and stomach, where reduced
PIGR expression was found to correlate with lymph
node metastasis. In the present study, however, there
was no significant association between PIGR expression
and lymph node metastasis, but high PIGR expression
was significantly associated with a less advanced T-stage
and uninvolved resection margins. These findings are also
in line with the majority of previous studies on other
cancer forms, indicating an association between highPIGR expression and a better prognosis; e.g. in colorectal
cancer [11], bladder cancer [14], and non-small cell lung
cancer [12]. To date, only one study on HCC has demon-
strated an association between high PIGR expression
and a higher metastatic potential and worse clinical
outcome [16].
Comprehensive longitudinal expression analysis revealed
that PIGR expression was significantly higher in sampled
IM, while PIGR was not expressed in squamous epithe-
lium, and weakly/focally expressed in normal gastric
mucosa. These findings are also in line with Gologan
et al., where PIGR was found to be uniformly expressed
Table 2 Associations of PIGR expression in primary tumours with clinicopathological parameters in the entire cohort











≤ average 0.610(0.00-3.00) 0.347 1.059(0.00-3.00) 0.217 0.010(0.00-2.75) 0.034 1.250(0.00-3.00) 0.538
>average 0.605(0.00-3.00) 0.120(0.00-3.00) 1.200(0.00-3.00) 0.987(0.00-3.00)
Gender
Female 0.375(0.00-3.00) 0.817 0.275(0.00-2.85) 0.816 0.330(0.00-3.00) 0.570 0.762(0.00-3.00) 0.915
Male 0.810(0.00-3.00) 0.375(0.00-3.00) 0.342(0.00-3.00) 1.225(0.00-3.00)
T-stage
T1 1.930(0.00-3.00) 0.002 2.031(0.12-2.70) 0.006 1.610(1.60-1.96) 0.154 1.970(0.80-3.00) 0.157
T2 1.100(0.00-3.00) 1.150(0.00-3.00) 0.225(0.00-2.20) 1.250(0.00-3.00)
T3 0.200(0.00-3.00) 0.062(0.00-2.85) 0.342(0.00-3.00) 0.370(0.00-3.00)
T4 0.128(0.00-3.00) 0.050(0.00-2.18) 0.000(0.00-1.06) 0.717(0.00-3.00)
N-stage
N0 1.200(0.00-3.00) 0.193 1.560(0.00-2.70) 0.065 1.361(0.00-3.00) 0.221 1.150(0.00-3.00) 0.043
N1 0.120(0.00-3.00) 0.040(0.00-3.00) 1.610(0.00-2.75) 0.023(0.00-2.03)
N2 0.375(0.00-3.00) 0.375(0.00-3.00) 0.017(0.00-3.00) 1.021(0.00-3.00)
N3 0.500(0.00-3.00) 0.100(0.00-1.60) 0.135(0.00-2.32) 2.325(0.00-3.00)
M-stage
M0 0.658(0.00-3.00) 0.633 0.312(0.00-3.00) 0.828 0.570(0.00-3.00) 0.493 1.150(0.00-3.00) 0.609
M1 0.238(0.00-3.00) 0.460(0.00-2.00) 0.020(0.00-2.32) 2.05(0.02-2.85)
Differentiation grade
High-moderate 0.671(0.00-3.00) 0.986 1.026(0.00-2.85) 0.579 0.756(0.00-3.00) 0.307 0.600(0.00-3.00) 0.480
Low 0.605(0.00-3.00) 0.140(0.00-3.00) 0.122(0.00-3.00) 1.262(0.00-3.00)
Resection margin
R0 1.032(0.00-3.00) 0.034 1.020(0.00-3.00) 0.249 1.069(0.00-3.00) 0.236 1.237(0.00-3.00) 0.282
R1 0.010((0.00-3.00) 0.000(0.00-2.18 0.000(0.00-3.00) 0.022(0.00-3.00)
R2 0.690(0.00-2.85) 0.660(0.00-2.85) 0.970(0.00-2.18) 0.125(0.03-1.80)
Location
Esophagus 0.375(0.00-3.00) 0.094 - - -
GE-junction 0.342(0.00-3.00) - - -
Stomach 1.150(0.00-3.00) - - -
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Another finding that confirms the results by Gologan
et al. is that PIGR expression did not differ in primary
tumours/lymph node metastases according to the presence
or absence of IM, indicating that PIGR is not associated
with carcinogenetic pathways originating in a background
of BE or gastric IM. Furthermore, the utility of PIGR as an
indicator of high-risk BE or gastric IM is not evident, as
the expression did not differ according to the presence/
absence of dysplasia, nor by the degree of dysplasia.
There was a tendency towards a lower PIGR expression
in lymph node metastases as compared to primary tu-
mours, although these results were not significant. This
finding is however in line with the hypothesis that PIGR
expression has tumour-inhibiting properties. Furthermorethe lack of positive conversion of PIGR expression from
the primary tumour to lymph node metastasis, suggests
that analysis of PIGR in the primary tumour should be
sufficient for prognostication purposes.
Of note, although the independent prognostic value of
PIGR expression was retained when adjusting for tumour
location in the multivariable model, stratified analysis
according to location revealed that the prognostic value
of PIGR was largely attributed to tumours located to the
esophagus and GEJ, and that PIGR expression was not
an independent prognostic factor in separate analysis
by tumour location. However, since the number of cases
available for analysis in each subgroup was rather small,
future studies encompassing tumours from larger pa-
tient cohorts are warranted to determine whether the
Figure 3 Kaplan-Meier estimates of overall and recurrence free survival according to PIGR expression. Overall survival according to
PIGR expression in (A) the entire cohort, and in (B) cases with R0 resection. Recurrence free survival in (C) cases with R0 resection, and in (D)
distant-metastasis free (M0) patients with R0 resection.
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location in these cancer forms. In this context, the
observation of a significant association between PIGR
expression and a more advanced N-stage in gastric cancer
is noteworthy, since the prognostic value of PIGR was not
evident in this category. Nevertheless, it should be accept-
able to consider adenocarcinomas of the esophagus,
GEJ and stomach as a group in biomarker studies, since
their clinical and biological differences and similarities
are likely more appropriately distinguished by their mo-
lecular characteristics, yet to be better defined, than by
their anatomical origin. Moreover, while the distribution
of some clinicopathological characteristics differed by ana-
tomical location in the present cohort, adjuvant treatment
and survival was similar for all categories.
It should also be pointed out that use of a CRT
analysis-derived cut off to determine the prognosticvalue of PIGR expression may lead to overfitting of the
model. Therefore analyses should be regarded as descrip-
tive and the same cut off value should be applied in
validatory studies on independent patient cohorts.
In the here analysed retrospective cohort, all cases of
neoadjuvant chemotherapy had been excluded and only
a minor proportion had received adjuvant chemotherapy.
Thus, the favourable prognosis conveyed by a high PIGR
expression is not likely due to an adjuvant treatment
effect. It would however be of interest to investigate a
potential link between PIGR expression and anti-tumoural
immune response in future studies and along this line,
whether PIGR may predict the response to neoadjuvant
or adjuvant chemotherapy [18,19]. Polymorphonuclear
neutrophils (PMNs) that are generally believed to be
antitumorigenic [20] have also been reported to actu-
ally facilitate tumour progression and invasion [21,22].
Table 3 Relative risks of death according to clinicopathological factors and PIGR expression – entire cohort and curatively treated patients with radically
resected primary tumours
Entire cohort R0 resection
n (events) Unadjusted HR (95% CI) p-value Adjusted HR (95% CI) p-value n (events) Unadjusted HR (95% CI) p-value Adjusted HR (95% CI) p-value
Age
Continuous 173 1.03 (1.01-1.05) <0.001 1.04 (1.03-1.06) <0.001 120 (65) 1.05 (1.02-1.07) <0.001 1.07 (1.04-1.09) <0.001
Gender
Female 41 (29) 1.00 1.00 26 (15) 1.00 1.00
Male 132 (82) 0.75 (0.49-1.14) 0.177 1.16 (0.11-1.90) 0.544 94 (50) 0.85 (0.48-1.52) 0.584 1.05 (0.57-1.94) 0.882
T-stage
T1 18 (5) 1.00 1.00 18 (5) 1.00 1.00
T2 32 (17) 2.30 (0.85-6.25) 0.102 1.36 (0.47-3.88) 0.568 31 (17) 2.43 (0.89-6.60) 0.082 1.39 (0.46-4.26) 0.560
T3 93 (66) 3.79 (1.52-9.44) 0.004 1.43 (0.51-3.96) 0.495 55 (34) 2.94 (1.15-7.53) 0.025 1.23 (0.40-3.72) 0.716
T4 27 (21) 5.59 (2.09-14.90) 0.001 2.12 (0.72-6.28) 0.175 15 (9) 3.34 (1.11-9.99) 0.031 1.30 (0.34-4.96) 0.697
N-stage
N0 58 (27) 1.00 1.00 46 (18) 1.00 1.00
N1 29 (17) 1.41 (0.77-2.59) 0.266 1.61 (0.86-2.98) 0.133 22 (11) 1.40 (0.66-2.97) 0.380 1.95 (0.90-4.21) 0.089
N2 41 (30) 2.06 (1.22-3.47) 0.007 2.28 (1.32-3.93) 0.003 27 (17) 2.03 (1.04-3.94) 0.037 3.02 (1.51-6.05) 0.002
N3 45 (37) 3.22 (1.94-5.33) <0.001 3.14 (1.81-5.45) <0.001 25 (19) 3.45 (1.80-6.64) <0.001 4.95 (2.46-9.93) <0.001
M-stage
M0 136 (83) 1.00 1.00 97 (50) 1.00 1.00
M1 18 (16) 2.23 (1.30-3.82) 0.004 1.69 (0.95-3.00) 0.072 10 (9) 2.78 (1.36-5.67) 0.005 1.54 (0.67-3.53) 0.311
Differentiation
High-moderate 46 (26) 1.00 1.00 37 (19) 1.00 1.00
Low 102 (75) 1.50 (0.96-2.34) 0.077 1.36 (0.85-2.17) 0.204 65 (40) 1.23 (0.71-2.12) 0.466 1.42 (0.81-2.49) 0.226
Margins
R0 123 (68) 1.00 1.00 1.00 1.00
R1 31 (27) 2.75 (1.76-4.30) <0.001 2.15 (1.34-3.46) 0.002 - -
R2 19 (16) 2.34 (1.35-4.07) 0.003 2.31 (1.30-4.11) 0.004 - -
Location
Esophagus 59 (33) 1.00 1.00 37 (16) 1.00 1.00
GE-junction 45 (31) 1.32 (0.81-2.16) 0.266 1.51 (0.90-2.56) 0.120 30 (18) 1.44 (0.74-2.83) 0.286 1.26 (0.62-2.58) 0.523
Stomach 65 (44) 1.26 (0.80-1.94) 0.311 1.59 (0.96-2.63) 0.069 50 (29) 1.44 (0.78-2.66) 0.237 1.41 (0.63-3.16) 0.409
PIGR expression
Low 92 (66) 1.00 1.00 37 (58) 1.00 1.00

















Table 4 Relative risks of recurrence according to clinicopathological factors and PIGR expression in radically resected primary tumours (R0) and in curatively
treated patients (R0 +M0)
R0 resection R0 resection +M0
n (events) Unadjusted HR (95% CI) p-value Adjusted HR (95% CI) p-value n (events) Unadjusted HR (95% CI) p-value Adjusted HR (95% CI) p-value
Age
Continuous 105 (46) 1.00 (0.98-1.03) 0.728 1.04 (1.01-1.08) 0.005 87 (35) 1.00 (0.97-1.03) 0.887 1.04 (1.00-1.07) 0.049
Gender
Female 20 (5) 1.00 1.00 16 (3) 1.00 1.00
Male 85 (41) 2.04 (0.81-5.18) 0.132 1.97 (0.73-5.36) 0.183 71 (32) 2.78 (0.85-9.07) 0.091 4.43 (1.21-16.24) 0.025
T-stage
T1 16 (3) 1.00 1.00 11 (1) 1.00 1.00
T2 28 (10) 2.32 (0.64-8.44) 0.201 1.78 (0.41-7.75) 0.440 24 (7) 3.66 (0.45-29.73) 0.225 2.45 (0.26-22.66) 0.430
T3 48 (25) 3.71 (1.12-12.34) 0.032 1.90 (0.46-7.72) 0.372 43 (22) 7.21 (0.97-53.55) 0.053 3.07 (0.36-26.02) 0.304
T4 12 (8) 6.50 (1.71-24.70) 0.006 2.07 (0.42-10.26) 0.372 8 (5) 11.29 (1.31-97.00) 0.027 4.50 (0.39-51.49) 0.226
N-stage
N0 41 (3) 1.00 1.00 37 (3) 1.00 1.00
N1 19 (11) 10.52 (2.92-37.85) <0.001 13.86 (3.72-51.70) <0.001 17 (10) 9.31 (2.56-33.87) 0.001 10.11 (2.61-39.22) 0.001
N2 26 (16) 12.97 (3.77-44.67) <0.001 15.68 (4.44-55.41) <0.001 22 (3) 11.22 (3.19-39.52) <0.001 14.68 (3.85-55.92) <0.001
N3 19 (16) 23.32 (6.75-80.56) <0.001 30.25 (8.48-107.93) <0.001 11 (9) 19.22 (5.13-71.98) <0.001 46.878 (10.56-208.038) <0.001
M-stage
M0 87 (35) 1.00 1.00 - -
M1 7 (6) 4.17 (1.74-10.01) 0.001 2.26 (0.77-6.69) 0.139 - -
Differentiation
High-moderate 32 (9) 1.00 1.00 31 (9) 1.00 1.00
Low 55 (31) 2.31 (1.10-4.86) 0.027 2.59 (1.20-5.61) 0.016 39 (20) 1.91 (0.87-4.19) 0.108 1.20 (0.43-3.34) 0.727
Location
Esophagus 32 (12) 26 (8) 1.00
GE-junction 27 (15) 1.81 (0.84-3.89) 0.128 1.92 (0.80-4.64) 0.144 25 (13) 2.00 (1.83-0.83-4.84) 0.122 3.22 (1.19-8.75) 0.022
Stomach 44 (19) 1.29 (0.63-2.67) 0.484 1.67 (0.66-4.26) 0.282 35 (14) 1.49 (0.63-3.56) 0.367 3.86 (1.35-11.03) 0.011
PIGR expression
Low 41 (25) 1.00 1.00 33 (21) 1.00 1.00

















Figure 4 Kaplan-Meier estimates of overall and recurrence free survival according to PIGR expression in subgroups according to
tumour location. Overall survival in the entire cohort of patients with (A) esophageal cancer, (B) GE-junction cancer and (C) stomach cancer.
Overall survival in patients with R0 resection with (D) esophageal cancer, (E) GE-junction cancer and (F) stomach cancer. Recurrence free survival
in curatively treated patients/R0 resection with (G) esophageal cancer, (H) GE-junction cancer and (I) stomach cancer.
Fristedt et al. Journal of Translational Medicine 2014, 12:83 Page 11 of 13
http://www.translational-medicine.com/content/12/1/83It is known from previous studies that SC, the extracellu-
lar part of PIGR, is able to inhibit interleukin 8 (IL-8) and
in turn prevent chemotaxis of PMNs [23]. PMNs activatematrix metalloproteinase-2 (MMP-2), an enzyme involved
in angiogenesis [13], tentatively stimulating tumour pro-
gression and invasion [21,22]. Thus, an inhibitory effect
Fristedt et al. Journal of Translational Medicine 2014, 12:83 Page 12 of 13
http://www.translational-medicine.com/content/12/1/83of MMP-2 by SC could be a possible explanation for
the favourable outcome associated with a high tumour-
specific PIGR expression.
Since a variety of normal non-B cells and malignant
cells have also been found to produce immunoglobulins
[24], another interesting avenue of research would be to
examine the functional interplay between PIGR and cancer
cell-associated immunoglobulins. The accumulated experi-
mental evidence so far indicates that such atypical immu-
noglobulins promote growth and proliferation of cancer
cells [25,26], in turn suggesting that PIGR may regulate
these immunoglobulins negatively in the majority of cancer
forms, including upper gastrointestinal adenocarcinoma.
A limitation to the present study is the retrospective
setting, where curative intent may be difficult to establish.
Therefore, we examined the risk of recurrence in relation
to PIGR expression in patients having R0 resection and R0
resection/no distant metastases (M0), respectively. In
the former category, cases denoted as having metastatic
disease had either be operated due to bleeding of the
primary tumour (with metastatic disease present) or
had non-locoregional lymph node metastases (M1). In
the prospective setting, curative treatment intent can
be mandatory for inclusion.
Another potential limitation is the use of the TMA
technique for all sampled tissue entities. There was,
however, no obvious heterogeneity in PIGR expression
between duplicate tissue cores, and of note duplicate
cores were obtained from different blocks of the primary
tumour and different lymph node metastases in cases with
more than one metastasis. Moreover, the TMA technique
is now an established tool for biomarker studies with equal
or even improved ability to identify associations between
investigative biomarkers and clinical outcome [27].
Conclusions
High PIGR expression is associated with a less advanced
T-stage and independently predicts a decreased risk of
recurrence and an improved survival in patients with
adenocarcinoma of the upper gastrointestinal tract. The
clinical relevance as well as the functional basis of these
observations merit further study.
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